Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Prospective, Randomized, Parallel-design, Multicenter Study to Evaluate the Safety of Icon Bioscience-10090 for the Treatment of Inflammation Associated With Cataract Surgery

Next Previous
Search
Trial Profile

A Phase 3, Prospective, Randomized, Parallel-design, Multicenter Study to Evaluate the Safety of Icon Bioscience-10090 for the Treatment of Inflammation Associated With Cataract Surgery

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 15 May 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dexamethasone (Primary) ; Prednisolone
  • Indications Ocular inflammation
  • Focus Adverse reactions; Registrational
  • Sponsors EyePoint Pharmaceuticals; Icon Bioscience

    • Most Recent Events

    • 08 May 2019 Results presented in the EyePoint Pharmaceuticals media release.
    • 06 Nov 2018 According to an EyePoint Pharmaceuticals media release, safety and efficacy data from this trial was published in the Journal of Cataract & Refractive Surgery.
    • 28 Mar 2018 According to an EyePoint Pharmaceuticals media release, pSivida Corp. acquired Icon Bioscience and subsequently changed its name to EyePoint Pharmaceuticals.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top